| Symbol | VSTM |
|---|---|
| Name | VERASTEM, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 117 KENDRICK STREET,SUITE 500, NEEDHAM, Massachusetts, 02494, United States |
| Telephone | +1 781 292-4200 |
| Fax | — |
| — | |
| Website | https://www.verastem.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001526119 |
| Description | Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. The companys first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The companys product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic, and other advanced cancers. Additional info from NASDAQ: |
2026-08-14 11:30
New Form SCHEDULE 13G/A - Verastem, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001172661-26-003623 <b>Size:</b> 10 KB
Read more
2026-08-07 12:11
New Form SCHEDULE 13G - Verastem, Inc. <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0000093751-26-000555 <b>Size:</b> 7 KB
Read more
2026-08-06 20:01
Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
Read more
2026-07-30 12:20
New Form SCHEDULE 13G/A - Verastem, Inc. <b>Filed:</b> 2026-07-30 <b>AccNo:</b> 0002012383-26-003122 <b>Size:</b> 10 KB
Read more
2026-07-23 20:32
📋 Gagnon Robert E. (Director) plans to sell 32K shares of Verastem, Inc. (at $5.89 each, total $188K) Filed: Jul 23, 2026 | ID: 000089
Read more
2026-07-23 11:30
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
Read more
2026-07-22 20:01
Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
Read more
2026-07-08 10:49
New Form SCHEDULE 13G/A - Verastem, Inc. <b>Filed:</b> 2026-07-08 <b>AccNo:</b> 0001172661-26-002511 <b>Size:</b> 10 KB
Read more
2026-07-02 20:30
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more
2026-06-25 20:01
📋 Gagnon Robert E. (Director) plans to sell 21K shares of Verastem, Inc. (at $4.21 each, total $90K) Filed: Jun 25, 2026 | ID: 000075
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT02215629 | Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia | Phase1 | Relapsed or Refractory Acute Myeloid Leukemia | Withdrawn | — | 2016-11-01 | ClinicalTrials.gov |
| NCT07747506 | Continued Access to Avutometinib in Combination With Defactinib in Patients Wit… | Phase2 | Low Grade Ovarian Serous Adenocarcinoma | Not_Yet_Recruiting | 2026-08-03 | 2028-08-01 | ClinicalTrials.gov |
| NCT07659795 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer | Phase2 | Colorectal Cancer | Recruiting | 2026-07-28 | 2028-12-01 | ClinicalTrials.gov |
| NCT07659782 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lu… | Phase2 | Non-Small Cell Lung Cancer | Recruiting | 2026-07-22 | 2028-12-01 | ClinicalTrials.gov |
| NCT07644559 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer | Phase2 | Pancreatic Ductal Adenocarcinoma (PDAC) | Recruiting | 2026-06-16 | 2028-12-01 | ClinicalTrials.gov |
| NCT07318324 | Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutan… | Phase1 | Phase IB | Recruiting | 2026-05-13 | 2030-08-01 | ClinicalTrials.gov |
| NCT07126158 | Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Panc… | Phase2 | Pancreatic Adenocarcinoma | Recruiting | 2026-04-10 | 2030-04-30 | ClinicalTrials.gov |
| NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | Phase1 | Pancreatic Ductal Adenocarcinoma | Recruiting | 2025-06-24 | 2028-12-01 | ClinicalTrials.gov |
| NCT06630260 | 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours | Phase1 | Glioblastoma Multiforme (GBM) | Recruiting | 2024-11-15 | 2030-09-30 | ClinicalTrials.gov |
| NCT06682572 | A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Canc… | Phase2 | Low Grade Serous Ovarian Cancer | Active_Not_Recruiting | 2024-10-30 | 2027-10-01 | ClinicalTrials.gov |
| NCT06487221 | Avutometinib and Defactinib in Diffuse Gastric Cancer | Phase2 | Gastric Cancer | Recruiting | 2024-10-28 | 2029-05-30 | ClinicalTrials.gov |
| NCT06394804 | A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Ser… | Phase2 | Low-Grade Serous Ovarian Cancer | Recruiting | 2024-04-29 | 2027-04-01 | ClinicalTrials.gov |
| NCT06194929 | Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of … | Phase1 | Cutaneous Melanoma | Recruiting | 2024-03-20 | 2030-01-15 | ClinicalTrials.gov |
| NCT06072781 | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade… | Phase3 | Low Grade Serous Ovarian Cancer | Recruiting | 2024-03-18 | 2031-02-09 | ClinicalTrials.gov |
| NCT06007924 | A Study of Avutometinib and Defactinib in People With Thyroid Cancer | Phase2 | Thyroid Cancer | Recruiting | 2023-08-16 | 2027-08-16 | ClinicalTrials.gov |
| NCT05798507 | Identification of Treatment Concentrations of Defactinib or VS-6766 for the Tre… | Early_Phase1 | Glioblastoma | Active_Not_Recruiting | 2023-07-28 | 2027-12-03 | ClinicalTrials.gov |
| NCT05669482 | Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel… | Phase1 | KRAS Activating Mutation | Active_Not_Recruiting | 2023-03-22 | 2027-08-31 | ClinicalTrials.gov |
| NCT05787561 | A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gyn… | Phase2 | Mesonephric Gynecologic Cancer | Recruiting | 2023-03-15 | 2027-03-01 | ClinicalTrials.gov |
| NCT05608252 | VS-6766+Abema+Fulv in Met HR+/HER- BC | Phase1 | Breast Cancer | Recruiting | 2023-02-23 | 2028-12-31 | ClinicalTrials.gov |
| NCT05512208 | A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib | Phase2 | Endometrioid Cancer | Recruiting | 2023-02-06 | 2029-12-01 | ClinicalTrials.gov |
| NCT05200442 | A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer | Phase1 | Colorectal Cancer | Suspended | 2022-08-22 | 2027-05-01 | ClinicalTrials.gov |
| NCT05375994 | Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients | Phase1 | Non Small Cell Lung Cancer | Completed | 2022-08-01 | 2026-06-15 | ClinicalTrials.gov |
| NCT05074810 | Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactini… | Phase1 | Non Small Cell Lung Cancer | Active_Not_Recruiting | 2022-04-12 | 2027-04-01 | ClinicalTrials.gov |
| NCT05187169 | Food Effect of VS-6766 in Healthy Adult Subjects | Phase1 | Food Effect | Completed | 2021-12-16 | 2022-04-12 | ClinicalTrials.gov |
| NCT04331041 | Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced … | Phase2 | Pancreas Cancer | Active_Not_Recruiting | 2021-08-24 | 2027-04-21 | ClinicalTrials.gov |
| NCT04720417 | Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Mela… | Phase2 | Metastatic Uveal Melanoma | Terminated | 2021-01-26 | 2024-04-30 | ClinicalTrials.gov |
| NCT04620330 | A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KR… | Phase2 | Non Small Cell Lung Cancer | Completed | 2020-12-31 | 2023-12-12 | ClinicalTrials.gov |
| NCT04625270 | A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Rec… | Phase2 | Low Grade Ovarian Serous Adenocarcinoma | Active_Not_Recruiting | 2020-12-21 | 2026-12-01 | ClinicalTrials.gov |
| NCT04487886 | Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavi… | Phase2 | COVID-19 | Completed | 2020-11-18 | 2021-06-10 | ClinicalTrials.gov |
| NCT04372602 | Duvelisib to Combat COVID-19 | Phase2 | COVID-19 | Completed | 2020-10-12 | 2022-03-02 | ClinicalTrials.gov |
| NCT03727880 | Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a N… | Phase2 | Resectable Pancreatic Ductal Adenocarcinoma (PDAC) | Completed | 2019-06-04 | 2025-01-15 | ClinicalTrials.gov |
| NCT03287271 | ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kin… | Phase1 | Ovarian Cancer | Terminated | 2018-02-06 | 2025-03-12 | ClinicalTrials.gov |
| NCT03875820 | Phase I Trial of Defactinib and VS-6766. | Phase1 | NSCLC | Active_Not_Recruiting | 2017-12-12 | 2026-10-31 | ClinicalTrials.gov |
| NCT02758587 | Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid… | Phase1 | Carcinoma, Non-small-cell Lung | Unknown | 2017-07-04 | 2021-12-01 | ClinicalTrials.gov |
| NCT02943317 | Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Prelimi… | Phase1 | Epithelial Ovarian Cancer | Terminated | 2016-10-01 | 2018-12-28 | ClinicalTrials.gov |
| NCT02546531 | Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advance… | Phase1 | Advanced Solid Tumors | Completed | 2016-02-03 | 2021-01-11 | ClinicalTrials.gov |
| NCT02651727 | Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and … | Phase1 | Pancreatic Cancer | Terminated | 2015-09-01 | 2017-01-01 | ClinicalTrials.gov |
| NCT02913716 | A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defacti… | Phase1 | Healthy Subjects | Completed | 2015-08-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02372227 | A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-… | Phase1 | Relapsed Malignant Mesothelioma | Terminated | 2015-01-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02004028 | Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Mali… | Phase2 | Malignant Pleural Mesothelioma | Terminated | 2013-12-12 | 2019-06-19 | ClinicalTrials.gov |
| NCT01991938 | Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematolo… | Phase1 | Non Hematologic Cancers | Terminated | 2013-11-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01943292 | Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematolo… | Phase1 | Non Hematologic Cancers | Completed | 2013-09-02 | 2014-06-09 | ClinicalTrials.gov |
| NCT01870609 | Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothel… | Phase2 | Malignant Pleural Mesothelioma | Terminated | 2013-09-01 | 2016-01-01 | ClinicalTrials.gov |
| NCT01951690 | Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Canc… | Phase2 | Non Small Cell Lung Cancer | Completed | 2013-09-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT02407509 | Phase I Trial of VS-6766 Alone and in Combination With Everolimus | Phase1 | Solid Tumours | Completed | 2013-06-17 | 2025-10-15 | ClinicalTrials.gov |
| NCT01849744 | Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hemato… | Phase1 | Non Hematologic Cancers | Terminated | 2013-06-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT01778803 | Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Adv… | Phase1 | Ovarian Cancer | Completed | 2013-02-26 | 2015-02-23 | ClinicalTrials.gov |
| NCT00787033 | A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies | Phase1 | Cancer | Completed | 2008-12-01 | 2012-02-01 | ClinicalTrials.gov |
| NCT00666926 | Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prosta… | Phase1 | Head and Neck Neoplasm | Completed | 2005-12-01 | 2009-04-01 | ClinicalTrials.gov |
Total clinical trials: 49
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Anastrozole | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| Letrozole | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| Paclitaxel | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| Pegylated liposomal doxorubicin | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| Defactinib | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| avutometinib | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| cetuximab | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| VS-7375 | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| Anastrozole | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| Letrozole | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| Paclitaxel | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| Pegylated liposomal doxorubicin | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| Defactinib | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| avutometinib | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| Cetuximab + mFOLFOX6 | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07659795 |
| panitumumab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07659795 |
| cetuximab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07659795 |
| VS-7375 | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07659795 |
| VS-7375 | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | RECRUITING | NCT07659782 |
| VS-7375 | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | RECRUITING | NCT07659782 |
| cetuximab | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| VS-7375 | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| Cetuximab + mFOLFOX6 | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07659795 |
| panitumumab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07659795 |
| cetuximab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07659795 |
| VS-7375 | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07659795 |
| avutometinib + defactininb combination | Other | Phase PHASE2 | Low Grade Ovarian Serous Adenocarcinoma | NOT_YET_RECRUITING | NCT07747506 |
| cetuximab | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| VS-7375 | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| cetuximab | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| VS-7375 | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| Carboplatin | Other | Phase PHASE1 | Ovarian Cancer | TERMINATED | NCT03287271 |
| Paclitaxel | Other | Phase PHASE1 | Ovarian Cancer | TERMINATED | NCT03287271 |
| VS-6063 | Other | Phase PHASE1 | Ovarian Cancer | TERMINATED | NCT03287271 |
| Anastrozole | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| Letrozole | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| Paclitaxel | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| Pegylated liposomal doxorubicin | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| Defactinib | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| avutometinib | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| VS-7375 | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | RECRUITING | NCT07659782 |
| cetuximab | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| VS-7375 | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| cetuximab | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| VS-7375 | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| Anastrozole | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| Letrozole | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| Paclitaxel | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| Pegylated liposomal doxorubicin | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| Defactinib | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| avutometinib | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| Cetuximab + mFOLFOX6 | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07659795 |
| panitumumab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07659795 |
| cetuximab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07659795 |
| VS-7375 | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07659795 |
| Defactinib | Other | Phase PHASE2 | Mesonephric Gynecologic Cancer | RECRUITING | NCT05787561 |
| Avutometinib (VS-6766) | Other | Phase PHASE2 | Mesonephric Gynecologic Cancer | RECRUITING | NCT05787561 |
| Letrozole | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Defactinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Avutometinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Cetuximab + mFOLFOX6 | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07659795 |
| panitumumab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07659795 |
| cetuximab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07659795 |
| VS-7375 | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07659795 |
| cetuximab | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| VS-7375 | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| cetuximab | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| VS-7375 | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| cetuximab | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| VS-7375 | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| Cetuximab + mFOLFOX6 | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07659795 |
| panitumumab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07659795 |
| cetuximab | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07659795 |
| VS-7375 | Other | Phase PHASE2 | Colorectal Cancer | RECRUITING | NCT07659795 |
| avutometinib (VS-6766) and adagrasib | Other | Phase PHASE1 | Non Small Cell Lung Cancer | COMPLETED | NCT05375994 |
| cetuximab | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| VS-7375 | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| cetuximab | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| VS-7375 | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| Everolimus | Other | Phase PHASE1 | Phase IB | RECRUITING | NCT07318324 |
| defactinib | Other | Phase PHASE1 | Phase IB | RECRUITING | NCT07318324 |
| Avutometinib | Other | Phase PHASE1 | Phase IB | RECRUITING | NCT07318324 |
| cetuximab | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| VS-7375 | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| cetuximab | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| VS-7375 | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| cetuximab | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| VS-7375 | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| Defactinib | Other | Phase PHASE2 | Thyroid Cancer | RECRUITING | NCT06007924 |
| Avutometinib | Other | Phase PHASE2 | Thyroid Cancer | RECRUITING | NCT06007924 |
| Cetuximab + mFOLFOX6 | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07659795 |
| panitumumab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07659795 |
| cetuximab | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07659795 |
| VS-7375 | Other | Phase PHASE2 | Colorectal Cancer | NOT_YET_RECRUITING | NCT07659795 |
| VS-7375 | Other | Phase PHASE2 | Non-Small Cell Lung Cancer | NOT_YET_RECRUITING | NCT07659782 |
| cetuximab | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| VS-7375 | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| cetuximab | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| VS-7375 | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma (PDAC) | RECRUITING | NCT07644559 |
| Research blood draw | Other | Phase PHASE2 | Pancreas Cancer | ACTIVE_NOT_RECRUITING | NCT04331041 |
| Tumor biopsy | Other | Phase PHASE2 | Pancreas Cancer | ACTIVE_NOT_RECRUITING | NCT04331041 |
| Defactinib | Other | Phase PHASE2 | Pancreas Cancer | ACTIVE_NOT_RECRUITING | NCT04331041 |
| Adaptive stereotactic body radiation therapy | Drug | Phase PHASE2 | Pancreas Cancer | ACTIVE_NOT_RECRUITING | NCT04331041 |
| Pill Diary | Other | Phase PHASE1 | Colorectal Cancer | SUSPENDED | NCT05200442 |
| Cetuximab | Other | Phase PHASE1 | Colorectal Cancer | SUSPENDED | NCT05200442 |
| VS-6766/avutometinib | Other | Phase PHASE1 | Colorectal Cancer | SUSPENDED | NCT05200442 |
| Research blood draw | Other | Phase PHASE2 | Pancreas Cancer | ACTIVE_NOT_RECRUITING | NCT04331041 |
| Tumor biopsy | Other | Phase PHASE2 | Pancreas Cancer | ACTIVE_NOT_RECRUITING | NCT04331041 |
| Defactinib | Other | Phase PHASE2 | Pancreas Cancer | ACTIVE_NOT_RECRUITING | NCT04331041 |
| Adaptive stereotactic body radiation therapy | Drug | Phase PHASE2 | Pancreas Cancer | ACTIVE_NOT_RECRUITING | NCT04331041 |
| Pill Diary | Other | Phase PHASE1 | Colorectal Cancer | SUSPENDED | NCT05200442 |
| Cetuximab | Other | Phase PHASE1 | Colorectal Cancer | SUSPENDED | NCT05200442 |
| VS-6766/avutometinib | Other | Phase PHASE1 | Colorectal Cancer | SUSPENDED | NCT05200442 |
| Research blood draw | Other | Phase PHASE2 | Pancreas Cancer | ACTIVE_NOT_RECRUITING | NCT04331041 |
| Tumor biopsy | Other | Phase PHASE2 | Pancreas Cancer | ACTIVE_NOT_RECRUITING | NCT04331041 |
| Defactinib | Other | Phase PHASE2 | Pancreas Cancer | ACTIVE_NOT_RECRUITING | NCT04331041 |
| Adaptive stereotactic body radiation therapy | Drug | Phase PHASE2 | Pancreas Cancer | ACTIVE_NOT_RECRUITING | NCT04331041 |
| Pill Diary | Other | Phase PHASE1 | Colorectal Cancer | SUSPENDED | NCT05200442 |
| Cetuximab | Other | Phase PHASE1 | Colorectal Cancer | SUSPENDED | NCT05200442 |
| VS-6766/avutometinib | Other | Phase PHASE1 | Colorectal Cancer | SUSPENDED | NCT05200442 |
| Research blood draw | Other | Phase PHASE2 | Pancreas Cancer | ACTIVE_NOT_RECRUITING | NCT04331041 |
| Tumor biopsy | Other | Phase PHASE2 | Pancreas Cancer | ACTIVE_NOT_RECRUITING | NCT04331041 |
| Defactinib | Other | Phase PHASE2 | Pancreas Cancer | ACTIVE_NOT_RECRUITING | NCT04331041 |
| Adaptive stereotactic body radiation therapy | Drug | Phase PHASE2 | Pancreas Cancer | ACTIVE_NOT_RECRUITING | NCT04331041 |
| Pill Diary | Other | Phase PHASE1 | Colorectal Cancer | SUSPENDED | NCT05200442 |
| Cetuximab | Other | Phase PHASE1 | Colorectal Cancer | SUSPENDED | NCT05200442 |
| VS-6766/avutometinib | Other | Phase PHASE1 | Colorectal Cancer | SUSPENDED | NCT05200442 |
| Pill Diary | Other | Phase PHASE1 | Colorectal Cancer | SUSPENDED | NCT05200442 |
| Cetuximab | Other | Phase PHASE1 | Colorectal Cancer | SUSPENDED | NCT05200442 |
| VS-6766/avutometinib | Other | Phase PHASE1 | Colorectal Cancer | SUSPENDED | NCT05200442 |
| VS-5584 and VS-6063 | Other | Phase PHASE1 | Relapsed Malignant Mesothelioma | TERMINATED | NCT02372227 |
| Biopsy | Other | Phase PHASE2 | Metastatic Uveal Melanoma | TERMINATED | NCT04720417 |
| Raf/MEK Inhibitor VS-6766 | Other | Phase PHASE2 | Metastatic Uveal Melanoma | TERMINATED | NCT04720417 |
| Defactinib Hydrochloride | Other | Phase PHASE2 | Metastatic Uveal Melanoma | TERMINATED | NCT04720417 |
| Defactinib | Other | Phase PHASE2 | Gastric Cancer | RECRUITING | NCT06487221 |
| Avutometinib | Other | Phase PHASE2 | Gastric Cancer | RECRUITING | NCT06487221 |
| VS-4718 | Other | Phase PHASE1 | Relapsed or Refractory Acute Myeloid Leukemia | WITHDRAWN | NCT02215629 |
| VS-5584 | Other | Phase PHASE1 | Non Hematologic Cancers | TERMINATED | NCT01991938 |
| defactinib | Other | Phase PHASE1 | Healthy Subjects | COMPLETED | NCT02913716 |
| Placebo | Other | Phase PHASE2 | Malignant Pleural Mesothelioma | TERMINATED | NCT01870609 |
| defactinib (VS-6063) | Other | Phase PHASE2 | Malignant Pleural Mesothelioma | TERMINATED | NCT01870609 |
| Defactinib | Other | Phase PHASE1 | Non Hematologic Cancers | COMPLETED | NCT01943292 |
| defactinib (VS-6063) | Other | Phase PHASE2 | Non Small Cell Lung Cancer | COMPLETED | NCT01951690 |
| Paclitaxel | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT01778803 |
| defactinib | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT01778803 |
| Part A- VS-4718, nab-paclitaxel, gemcitabine | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT02651727 |
| Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT02651727 |
| Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine | Other | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT02651727 |
| VS-4718 | Other | Phase PHASE1 | Non Hematologic Cancers | TERMINATED | NCT01849744 |
| Pembrolizumab | Other | Phase PHASE1 | Carcinoma, Non-small-cell Lung | UNKNOWN | NCT02758587 |
| Defactinib | Other | Phase PHASE1 | Carcinoma, Non-small-cell Lung | UNKNOWN | NCT02758587 |
| Part A - Avelumab | Other | Phase PHASE1 | Epithelial Ovarian Cancer | TERMINATED | NCT02943317 |
| Part A - VS-6063 | Other | Phase PHASE1 | Epithelial Ovarian Cancer | TERMINATED | NCT02943317 |
| Gemcitabine | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT02546531 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT02546531 |
| Defactinib | Other | Phase PHASE1 | Advanced Solid Tumors | COMPLETED | NCT02546531 |
| VS-6766 | Other | Phase PHASE1 | Food Effect | COMPLETED | NCT05187169 |
| Placebo | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04372602 |
| Peripheral blood draw | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04372602 |
| Duvelisib | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04372602 |
| Placebo | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04487886 |
| Duvelisib | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04487886 |
| avutometinib (VS-6766) and Defactinib | Other | Phase PHASE2 | Non Small Cell Lung Cancer | COMPLETED | NCT04620330 |
| avutometinib (VS-6766) | Other | Phase PHASE2 | Non Small Cell Lung Cancer | COMPLETED | NCT04620330 |
| VS-6063 | Other | Phase PHASE2 | Malignant Pleural Mesothelioma | TERMINATED | NCT02004028 |
| Carboplatin | Other | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT03287271 |
| Paclitaxel | Other | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT03287271 |
| VS-6063 | Other | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT03287271 |
| avutometinib (VS-6766) and defactinib | Other | Phase PHASE2 | Low Grade Ovarian Serous Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04625270 |
| avutometinib (VS-6766) | Other | Phase PHASE2 | Low Grade Ovarian Serous Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04625270 |
| avutometinib (VS-6766) and adagrasib | Other | Phase PHASE1 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05375994 |
| avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel | Other | Phase PHASE1 | KRAS Activating Mutation | ACTIVE_NOT_RECRUITING | NCT05669482 |
| Avutometinib (VS-6766) + Defactinib (VS-6063) | Other | Phase PHASE2 | Low Grade Serous Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06682572 |
| Avutometinib (VS-6766) + defactinib | Other | Phase PHASE2 | Endometrioid Cancer | RECRUITING | NCT05512208 |
| Fulvestrant | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT05608252 |
| Abemaciclib | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT05608252 |
| VS-6766 | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT05608252 |
| Encorafenib | Other | Phase PHASE1 | Cutaneous Melanoma | RECRUITING | NCT06194929 |
| Avutometinib | Other | Phase PHASE1 | Cutaneous Melanoma | RECRUITING | NCT06194929 |
| Defactinib | Other | Phase PHASE1 | Cutaneous Melanoma | RECRUITING | NCT06194929 |
| Defactinib | Other | Phase EARLY_PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT05798507 |
| Biospecimen Collection | Other | Phase EARLY_PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT05798507 |
| Avutometinib | Other | Phase EARLY_PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT05798507 |
| avutometinib and sotorasib and defactinib | Other | Phase PHASE1 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05074810 |
| avutometinib and sotorasib | Other | Phase PHASE1 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05074810 |
| Temozolomide | Other | Phase PHASE1 | Glioblastoma Multiforme (GBM) | RECRUITING | NCT06630260 |
| Defactinib | Other | Phase PHASE1 | Glioblastoma Multiforme (GBM) | RECRUITING | NCT06630260 |
| Avutometinib | Other | Phase PHASE1 | Glioblastoma Multiforme (GBM) | RECRUITING | NCT06630260 |
| Everolimus | Other | Phase PHASE1 | Solid Tumours | COMPLETED | NCT02407509 |
| VS-6766 | Other | Phase PHASE1 | Solid Tumours | COMPLETED | NCT02407509 |
| Defactinib | Other | Phase PHASE2 | Resectable Pancreatic Ductal Adenocarcinoma (PDAC) | COMPLETED | NCT03727880 |
| Pembrolizumab | Other | Phase PHASE2 | Resectable Pancreatic Ductal Adenocarcinoma (PDAC) | COMPLETED | NCT03727880 |
| Defactinib | Other | Phase PHASE1 | NSCLC | ACTIVE_NOT_RECRUITING | NCT03875820 |
| VS-6766 | Other | Phase PHASE1 | NSCLC | ACTIVE_NOT_RECRUITING | NCT03875820 |
| Research blood draw | Other | Phase PHASE2 | Pancreas Cancer | ACTIVE_NOT_RECRUITING | NCT04331041 |
| Tumor biopsy | Other | Phase PHASE2 | Pancreas Cancer | ACTIVE_NOT_RECRUITING | NCT04331041 |
| Defactinib | Other | Phase PHASE2 | Pancreas Cancer | ACTIVE_NOT_RECRUITING | NCT04331041 |
| Adaptive stereotactic body radiation therapy | Drug | Phase PHASE2 | Pancreas Cancer | ACTIVE_NOT_RECRUITING | NCT04331041 |
| Defactinib | Other | Phase PHASE2 | Thyroid Cancer | RECRUITING | NCT06007924 |
| Avutometinib | Other | Phase PHASE2 | Thyroid Cancer | RECRUITING | NCT06007924 |
| Pill Diary | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT05200442 |
| Cetuximab | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT05200442 |
| VS-6766/avutometinib | Other | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT05200442 |
| Anastrozole | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| Letrozole | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| Paclitaxel | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| Pegylated liposomal doxorubicin | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| Defactinib | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| avutometinib | Other | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| Avutometinib | Other | Phase PHASE2 | Pancreatic Adenocarcinoma | RECRUITING | NCT07126158 |
| Defactinib | Other | Phase PHASE2 | Pancreatic Adenocarcinoma | RECRUITING | NCT07126158 |
| Stereotactic body radiotherapy | Drug | Phase PHASE2 | Pancreatic Adenocarcinoma | RECRUITING | NCT07126158 |
| Gemcitabine + Nab-paclitaxel | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Gemcitabine | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Carboplatin + Pemetrexed + Pembrolizumab | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Cetuximab | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| VS-7375 | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Letrozole | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Defactinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Avutometinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Fulvestrant | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT05608252 |
| Abemaciclib | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT05608252 |
| VS-6766 | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT05608252 |
| Fulvestrant | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT05608252 |
| Abemaciclib | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT05608252 |
| VS-6766 | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT05608252 |
| Fulvestrant | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT05608252 |
| Abemaciclib | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT05608252 |
| VS-6766 | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT05608252 |
| Fulvestrant | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT05608252 |
| Abemaciclib | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT05608252 |
| VS-6766 | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT05608252 |
| Fulvestrant | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT05608252 |
| Abemaciclib | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT05608252 |
| VS-6766 | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT05608252 |
| Fulvestrant | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT05608252 |
| Abemaciclib | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT05608252 |
| VS-6766 | Other | Phase PHASE1 | Breast Cancer | RECRUITING | NCT05608252 |
| Defactinib | Other | Phase PHASE2 | Mesonephric Gynecologic Cancer | RECRUITING | NCT05787561 |
| Avutometinib (VS-6766) | Other | Phase PHASE2 | Mesonephric Gynecologic Cancer | RECRUITING | NCT05787561 |
| Defactinib | Other | Phase PHASE2 | Mesonephric Gynecologic Cancer | RECRUITING | NCT05787561 |
| Avutometinib (VS-6766) | Other | Phase PHASE2 | Mesonephric Gynecologic Cancer | RECRUITING | NCT05787561 |
| Defactinib | Other | Phase PHASE2 | Mesonephric Gynecologic Cancer | RECRUITING | NCT05787561 |
| Avutometinib (VS-6766) | Other | Phase PHASE2 | Mesonephric Gynecologic Cancer | RECRUITING | NCT05787561 |
| Defactinib | Other | Phase PHASE2 | Mesonephric Gynecologic Cancer | RECRUITING | NCT05787561 |
| Avutometinib (VS-6766) | Other | Phase PHASE2 | Mesonephric Gynecologic Cancer | RECRUITING | NCT05787561 |
| Defactinib | Other | Phase PHASE2 | Mesonephric Gynecologic Cancer | RECRUITING | NCT05787561 |
| Avutometinib (VS-6766) | Other | Phase PHASE2 | Mesonephric Gynecologic Cancer | RECRUITING | NCT05787561 |
| Defactinib | Other | Phase PHASE2 | Mesonephric Gynecologic Cancer | RECRUITING | NCT05787561 |
| Avutometinib (VS-6766) | Other | Phase PHASE2 | Mesonephric Gynecologic Cancer | RECRUITING | NCT05787561 |
| Defactinib | Other | Phase PHASE2 | Mesonephric Gynecologic Cancer | RECRUITING | NCT05787561 |
| Avutometinib (VS-6766) | Other | Phase PHASE2 | Mesonephric Gynecologic Cancer | RECRUITING | NCT05787561 |
| Defactinib | Other | Phase PHASE2 | Mesonephric Gynecologic Cancer | RECRUITING | NCT05787561 |
| Avutometinib (VS-6766) | Other | Phase PHASE2 | Mesonephric Gynecologic Cancer | RECRUITING | NCT05787561 |
| Defactinib | Other | Phase PHASE2 | Mesonephric Gynecologic Cancer | RECRUITING | NCT05787561 |
| Avutometinib (VS-6766) | Other | Phase PHASE2 | Mesonephric Gynecologic Cancer | RECRUITING | NCT05787561 |
| Defactinib | Other | Phase PHASE2 | Mesonephric Gynecologic Cancer | RECRUITING | NCT05787561 |
| Avutometinib (VS-6766) | Other | Phase PHASE2 | Mesonephric Gynecologic Cancer | RECRUITING | NCT05787561 |
| Letrozole | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Defactinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Avutometinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Letrozole | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Defactinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Avutometinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Letrozole | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Defactinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Avutometinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Letrozole | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Defactinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Avutometinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Letrozole | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Defactinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Avutometinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Letrozole | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Defactinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Avutometinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Letrozole | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Defactinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Avutometinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Letrozole | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Defactinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Avutometinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Letrozole | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Defactinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Avutometinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Letrozole | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Defactinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Avutometinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Gemcitabine + Nab-paclitaxel | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Gemcitabine | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Carboplatin + Pemetrexed + Pembrolizumab | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Cetuximab | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| VS-7375 | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Letrozole | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Defactinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Avutometinib | Other | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Gemcitabine + Nab-paclitaxel | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Gemcitabine | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Carboplatin + Pemetrexed + Pembrolizumab | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Cetuximab | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| VS-7375 | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Gemcitabine + Nab-paclitaxel | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Gemcitabine | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Carboplatin + Pemetrexed + Pembrolizumab | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Cetuximab | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| VS-7375 | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Gemcitabine + Nab-paclitaxel | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Gemcitabine | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Carboplatin + Pemetrexed + Pembrolizumab | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Cetuximab | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| VS-7375 | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Gemcitabine + Nab-paclitaxel | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Gemcitabine | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Carboplatin + Pemetrexed + Pembrolizumab | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Cetuximab | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| VS-7375 | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Gemcitabine + Nab-paclitaxel | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Gemcitabine | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Carboplatin + Pemetrexed + Pembrolizumab | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Cetuximab | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| VS-7375 | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Gemcitabine + Nab-paclitaxel | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Gemcitabine | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Carboplatin + Pemetrexed + Pembrolizumab | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Cetuximab | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| VS-7375 | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Gemcitabine + Nab-paclitaxel | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Gemcitabine | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Carboplatin + Pemetrexed + Pembrolizumab | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Cetuximab | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| VS-7375 | Other | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Stereotactic body radiotherapy | RADIATION | Phase PHASE2 | Pancreatic Adenocarcinoma | NOT_YET_RECRUITING | NCT07126158 |
| Gemcitabine + Nab-paclitaxel | DRUG | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Carboplatin + Pemetrexed + Pembrolizumab | DRUG | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| VS-7375 | DRUG | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Avutometinib (VS-6766) + Defactinib (VS-6063) | DRUG | Phase PHASE2 | Low Grade Serous Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06682572 |
| Temozolomide | DRUG | Phase PHASE1 | Glioblastoma Multiforme (GBM) | RECRUITING | NCT06630260 |
| Encorafenib | DRUG | Phase PHASE1 | Cutaneous Melanoma | RECRUITING | NCT06194929 |
| Anastrozole | DRUG | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| Letrozole | DRUG | Phase PHASE2 | Low-Grade Serous Ovarian Cancer | RECRUITING | NCT06394804 |
| Pegylated liposomal doxorubicin | DRUG | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| avutometinib | DRUG | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| Biospecimen Collection | PROCEDURE | Phase EARLY_PHASE1 | Glioblastoma | ACTIVE_NOT_RECRUITING | NCT05798507 |
| Avutometinib | DRUG | Phase PHASE1 | Phase IB | NOT_YET_RECRUITING | NCT07318324 |
| Avutometinib (VS-6766) | DRUG | Phase PHASE2 | Mesonephric Gynecologic Cancer | RECRUITING | NCT05787561 |
| avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel | DRUG | Phase PHASE1 | KRAS Activating Mutation | ACTIVE_NOT_RECRUITING | NCT05669482 |
| Fulvestrant | DRUG | Phase PHASE1 | Breast Cancer | RECRUITING | NCT05608252 |
| Abemaciclib | DRUG | Phase PHASE1 | Breast Cancer | RECRUITING | NCT05608252 |
| Avutometinib (VS-6766) + defactinib | DRUG | Phase PHASE2 | Endometrioid Cancer | RECRUITING | NCT05512208 |
| avutometinib (VS-6766) and adagrasib | DRUG | Phase PHASE1 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05375994 |
| Pill Diary | OTHER | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT05200442 |
| Cetuximab | DRUG | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| VS-6766/avutometinib | DRUG | Phase PHASE1 | Colorectal Cancer | RECRUITING | NCT05200442 |
| avutometinib and sotorasib and defactinib | DRUG | Phase PHASE1 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05074810 |
| avutometinib and sotorasib | DRUG | Phase PHASE1 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT05074810 |
| Biopsy | PROCEDURE | Phase PHASE2 | Metastatic Uveal Melanoma | TERMINATED | NCT04720417 |
| Raf/MEK Inhibitor VS-6766 | DRUG | Phase PHASE2 | Metastatic Uveal Melanoma | TERMINATED | NCT04720417 |
| Defactinib Hydrochloride | DRUG | Phase PHASE2 | Metastatic Uveal Melanoma | TERMINATED | NCT04720417 |
| avutometinib (VS-6766) and defactinib | DRUG | Phase PHASE2 | Low Grade Ovarian Serous Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04625270 |
| avutometinib (VS-6766) and Defactinib | DRUG | Phase PHASE2 | Non Small Cell Lung Cancer | COMPLETED | NCT04620330 |
| avutometinib (VS-6766) | DRUG | Phase PHASE2 | Low Grade Ovarian Serous Adenocarcinoma | ACTIVE_NOT_RECRUITING | NCT04625270 |
| Peripheral blood draw | PROCEDURE | Phase PHASE2 | COVID-19 | COMPLETED | NCT04372602 |
| Duvelisib | DRUG | Phase PHASE2 | COVID-19 | COMPLETED | NCT04487886 |
| Research blood draw | PROCEDURE | Phase PHASE2 | Pancreas Cancer | ACTIVE_NOT_RECRUITING | NCT04331041 |
| Tumor biopsy | PROCEDURE | Phase PHASE2 | Pancreas Cancer | ACTIVE_NOT_RECRUITING | NCT04331041 |
| Adaptive stereotactic body radiation therapy | DEVICE | Phase PHASE2 | Pancreas Cancer | ACTIVE_NOT_RECRUITING | NCT04331041 |
| Carboplatin | DRUG | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT03287271 |
| Part A - Avelumab | DRUG | Phase PHASE1 | Epithelial Ovarian Cancer | TERMINATED | NCT02943317 |
| Part A - VS-6063 | DRUG | Phase PHASE1 | Epithelial Ovarian Cancer | TERMINATED | NCT02943317 |
| Part A- VS-4718, nab-paclitaxel, gemcitabine | DRUG | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT02651727 |
| Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine | DRUG | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT02651727 |
| Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine | DRUG | Phase PHASE1 | Pancreatic Cancer | TERMINATED | NCT02651727 |
| Gemcitabine | DRUG | Phase PHASE1 | Pancreatic Ductal Adenocarcinoma | RECRUITING | NCT07020221 |
| Pembrolizumab | DRUG | Phase PHASE2 | Resectable Pancreatic Ductal Adenocarcinoma (PDAC) | COMPLETED | NCT03727880 |
| Everolimus | DRUG | Phase PHASE1 | Phase IB | NOT_YET_RECRUITING | NCT07318324 |
| VS-6766 | DRUG | Phase PHASE1 | Breast Cancer | RECRUITING | NCT05608252 |
| VS-5584 and VS-6063 | DRUG | Phase PHASE1 | Relapsed Malignant Mesothelioma | TERMINATED | NCT02372227 |
| Placebo | DRUG | Phase PHASE2 | COVID-19 | COMPLETED | NCT04487886 |
| VS-6063 | DRUG | Phase PHASE1 | Ovarian Cancer | RECRUITING | NCT03287271 |
| VS-5584 | DRUG | Phase PHASE1 | Non Hematologic Cancers | TERMINATED | NCT01991938 |
| defactinib (VS-6063) | DRUG | Phase PHASE2 | Non Small Cell Lung Cancer | COMPLETED | NCT01951690 |
| Defactinib | DRUG | Phase PHASE2 | Pancreatic Adenocarcinoma | NOT_YET_RECRUITING | NCT07126158 |
| VS-4718 | DRUG | Phase PHASE1 | Relapsed or Refractory Acute Myeloid Leukemia | WITHDRAWN | NCT02215629 |
| Paclitaxel | DRUG | Phase PHASE3 | Low Grade Serous Ovarian Cancer | RECRUITING | NCT06072781 |
| defactinib | DRUG | Phase PHASE1 | Phase IB | NOT_YET_RECRUITING | NCT07318324 |
| PF-04554878 | DRUG | Phase PHASE1 | Cancer | COMPLETED | NCT00787033 |
| PF00562271 | DRUG | Phase PHASE1 | Head and Neck Neoplasm | COMPLETED | NCT00666926 |
Total products: 387